Table 2.
Cancer type | Setting | Cancer line/ model/tissue | Pyroptotic component | Relative expression | Associated consequence(s) of relative expression | Ref |
---|---|---|---|---|---|---|
Breast cancer | In vivo: human | Primary tissue | GSDMB | Increased | ↑ Metastasis & ↓ Patient survival | [46] |
In vivo: human | Primary tissue | GSDME | Decreased | ↑ Metastasis | [47] | |
In vitro: - | MDA-MB-231 | Decreased* | ↑ Invasion | [47] | ||
In vivo: human | Primary tissue | Caspase-1 | Decreased | N/A | [48] | |
In vitro: - | MDA-MB-231 | Decreased* | ↑ Proliferation & Invasion | [48] | ||
In vivo: human | Primary tissue | NLRP1 | Increased | ↑ Metastasis | [49] | |
In vivo: mouse | MCF-7 | Increased | ↑ Tumorigenicity & Invasion | [49] | ||
Colorectal cancer | In vivo: mouse | LoVo | GSDMC | Increased | ↑ Tumor growth | [50] |
In vitro: - | DLD-1, LoVo | Increased | ↑ Proliferation | [50] | ||
In vivo: human | Primary tissue | GSDME | Decreased | N/A | [51] | |
In vitro: - | HCT116 | Decreased* | ↑ Cell growth | [51] | ||
In vivo: human | Primary tissue | AIM2 | Decreased | ↓ Patient survival | [52] | |
In vivo: mouse | AOM-DSS | Caspase-1 | Decreased* | ↑ Tumorigenesis | [53] | |
In vivo: human | Primary tissue | NLRP1 | Decreased | ↑ Metastasis & ↓ Patient survival | [54] | |
Gastric cancer | In vitro: - | MKN28 | GSDMA | Decreased | ↑ Cell growth | [55] |
In vivo: human | Primary tissue | GSDMB | Decreased | N/A | [35] | |
In vitro: - | MKN28 | Increased* | No change in cell growth | [56] | ||
In vitro: - | MKN28 | GSDMC | Increased* | ↓ Cell growth | [56] | |
In vivo: human | Primary tissue | GSDMD | Decreased | N/A | [57] | |
In vivo: mouse | BGC823 | Increased* | ↓ Tumor growth | [57] | ||
In vivo: human | Primary tissue | GSDME | Decreased | N/A | [58] | |
In vivo: mouse | AOM | Decreased* | No changes reported | [59] | ||
Glioma | In vivo: human | Primary tissue | Caspase-1 | Increased | N/A | [60] |
In vitro: - | U87, T98G | Increased* | ↑ Proliferation & Mobility | [60] | ||
Hepatocellular carcinoma | In vivo: human | Primary tissue | AIM2 | Decreased | ↑ Tumor progression | [61] |
In vitro: - | HuH-7 | Increased* | ↓ Proliferation & Invasion | [61] | ||
Lung cancer | In vivo: human | Primary tissue | GSDMD | Increased | ↑ Tumor size & | [27] |
In vivo: mouse | PC9 | Decreased* |
↑ Metastasis stage ↓ Tumor growth |
[27] | ||
Melanoma | In vitro: - | 1205Lu | NLRP1 | Increased* | ↑ TMZ resistance | [62] |
In vivo: human | Primary tissue | Decreased | N/A | [63] | ||
In vivo: mouse | 1205Lu | Decreased* | ↓ Tumor growth | [63] | ||
Prostate cancer | In vivo: human | Primary tissue | Caspase-1 | Decreased | N/A | [64] |
* indicates expression was forced or a consequence of experimental treatment during functional studies. The term relative expression is used broadly here and includes mRNA and/or protein level expression depending on the study. AIM2, absent in melanoma 2; AOM, azoxymethane; DSS, dextran sodium sulfate; GSDMA/B/C/D/E, gasdermin A/B/C/D/E; NLRP1, NLR family pyrin domain-containing 1; TMZ, temozolomide